The flavonoid apigenin reduces prostate cancer CD44+ stem cell survival and migration through PI3K/Akt/NF-κB signaling

Life Sciences

Volumn 162, Issue , 2016, Pages 77-86

  Erdogan, Suat ^a   Doganlar, Oguzhan ^a   Doganlar, Zeynep B ^a   Serttas, Riza ^a   Turkekul, Kader ^a   Dibirdik, Ilker ^a   Bilir, Ayhan ^b  

^a TRAKYA UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Apigenin; CD44+; Docetaxel; PC3; Prostate cancer; Stem cells; CSCs

Indexed keywords

APIGENIN; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 8; CYTOCHROME C; DOCETAXEL; GELATINASE A; GELATINASE B; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; ORGANIC CATION TRANSPORTER 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P105; PROTEIN P21; PROTEIN P27; PROTEIN P50; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL ADHESION; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CELL SELECTION; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANTIGENS, CD44; APIGENIN; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MALE; NEOPLASTIC STEM CELLS; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84984646296     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2016.08.019     Document Type: Article

References (56)

1. [1] Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136:5 (2015), E359–E386.
2. [2] Belpomme, D., Irigaray, P., Sasco, A.J., Newby, J.A., Howard, V., Clapp, R., Hardell, L., The growing incidence of cancer: role of lifestyle and screening detection (review). Int. J. Oncol. 30:5 (2007), 1037–1049.
3. [3] Feldman, B.J., Feldman, D., The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1:1 (2001), 34–45.
4. [4] Vinogradov, S., Wei, X., Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine 7:4 (2012), 597–615.
5. [5] Yang, M.Q., Liu, P.P., Huang, P., Cancer stem cells, metabolism, and therapeutic significance. Tumor Biol. 37:5 (2016), 5735–5742.
6. [6] Reya, T., Morrison, S.J., Clarke, M.F., Weissman, I.L., Stem cells, cancer, and cancer stem cells. Nature 414:6859 (2001), 105–111.
7. [7] Klonisch, T., Wiechec, E., Hombach-Kionisch, S., Ande, S.R., Wesselborg, S., Schulze-Osthoff, K., Los, M., Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol. Med. 14:10 (2008), 450–460.
8. [8] Sharpe, B., Beresford, M., Bowen, R., Mitchard, J., Chalmers, A.D., Searching for prostate cancer stem cells: markers and methods. Stem Cell Rev. Rep. 9:5 (2013), 721–730.
9. [9] Clarke, S.J., Rivory, L.P., Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet. 36:2 (1999), 99–114.
10. [10] Zhu, Y.Z., Liu, C.F., Nadiminty, N., Lou, W., Tummala, R., Evans, C.P., Gao, A.C., Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol. Cancer Ther. 12:9 (2013), 1829–1836.
11. [11] Fantini, M., Benvenuto, M., Masuelli, L., Frajese, G.V., Tresoldi, I., Modesti, A., Bei, R., In vitro and in vivo antitumoral effects of combinations of polyphenols, or polyphenols and anticancer drugs: perspectives on cancer treatment. Int. J. Mol. Sci. 16:5 (2015), 9236–9282.
12. [12] Kumar, S., Pandey, A.K., Chemistry and biological activities of flavonoids: an overview. Sci. World J., 2013.
13. [13] Patel, D., Shukla, S., Gupta, S., Apigenin and cancer chemoprevention: progress, potential and promise (review). Int. J. Oncol. 30:1 (2007), 233–245.
14. [14] Fang, J., Xia, C., Cao, Z.X., Zheng, J.Z., Reed, E., Jiang, B.H., Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J. 19:3 (2005), 342–353.
15. [15] Shukla, S., Gupta, S., Apigenin: a promising molecule for cancer prevention. Pharm Res-Dordr 27:6 (2010), 962–978.
16. [16] Shukla, S., Bhaskaran, N., Babcook, M.A., Fu, P.F., MacLennan, G.T., Gupta, S., Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway. Carcinogenesis 35:2 (2014), 452–460.
17. [17] Shukla, S., Gupta, S., Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol. Carcinog. 39:2 (2004), 114–124.
18. [18] Tong, X., Pelling, J.C., Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention. Anti-Cancer Agent Me 13:7 (2013), 971–978.
19. [19] Hessenauer, A., Montenarh, M., Gotz, C., Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells. Int. J. Oncol. 22:6 (2003), 1263–1270.
20. [20] Wang, L., Kuang, L.S., Hitron, J.A., Son, Y.O., Wang, X., Budhraja, A., Lee, J.C., Pratheeshkumar, P., Chen, G., Zhang, Z., et al. Apigenin suppresses migration and invasion of transformed cells through down-regulation of C-X-C chemokine receptor 4 expression. Toxicol. Appl. Pharmacol. 272:1 (2013), 108–116.
21. [21] Lynch, C.C., Matrisian, L.M., Matrix metalloproteinases in tumor - host cell communication. Differentiation 70:9–10 (2002), 561–573.
22. [22] Smith, B.N., Odero-Marah, V.A., The role of Snail in prostate cancer. Cell Adhes. Migr. 6:5 (2012), 433–441.
23. [23] Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25:4 (2001), 402–408.
24. [24] Shukla, S., Gupta, S., Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle 6:9 (2007), 1102–1114.
25. [25] Seo, H.S., Jo, J.K., Ku, J.M., Choi, H.S., Choi, Y.K., Woo, J.K., Kim, H.I., Kang, S.Y., Lee, K.M., Nam, K.W., et al. Induction of caspase-dependent extrinsic apoptosis by apigenin through inhibition of signal transducer and activator of transcription 3 (STAT3) signalling in HER2-overexpressing BT-474 breast cancer cells. Biosci. Rep., 35, 2015.
26. [26] Seo, Y.J., Kim, B.S., Chun, S.Y., Park, Y.K., Kang, K.S., Kwon, T.G., Apoptotic effects of genistein, biochanin-A and apigenin on LNCaP and PC-3 cells by p21 through transcriptional inhibition of polo-like kinase-1. J. Korean Med. Sci. 26:11 (2011), 1489–1494.
27. [27] Choi, E.J., Kim, G.H., 5-Fluorouracil combined with apigenin enhances anticancer activity through induction of apoptosis in human breast cancer MDA-MB-453 cells. Oncol. Rep. 22:6 (2009), 1533–1537.
28. [28] Hu, L., McArthur, C., Jaffe, R.B., Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br. J. Cancer 102:8 (2010), 1276–1283.
29. [29] Shukla, S., Gupta, S., Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation. Free Radic. Biol. Med. 44:10 (2008), 1833–1845.
30. [30] Shukla, S., Fu, P.F., Gupta, S., Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70-Bax interaction in prostate cancer. Apoptosis 19:5 (2014), 883–894.
31. [31] Choi, E.J., Kim, G.H., Apigenin induces apoptosis through a mitochondria/caspase-pathway in human breast cancer MDA-MB-453 cells. J. Clin. Biochem. Nutr. 44:3 (2009), 260–265.
32. [32] Choi, E.J., Kim, G.H., Apigenin causes G(2)/M arrest associated with the modulation of p21(Cip1) and Cdc2 and activates p53-dependent apoptosis pathway in human breast cancer SK-BR-3 cells. J. Nutr. Biochem. 20:4 (2009), 285–290.
33. [33] Lu, H.F., Chie, Y.J., Yang, M.S., Lu, K.W., Fu, J.J., Yang, J.S., Chen, H.Y., Hsia, T.C., Ma, C.Y., Ip, S.W., et al. Apigenin induces apoptosis in human lung cancer H460 cells through caspase- and mitochondria-dependent pathways. Hum. Exp. Toxicol. 30:8 (2011), 1053–1061.
34. [34] Morrissey, C., O'Neill, A., Spengler, B., Christoffel, V., Fitzpatrick, J.M., Watson, R.W., Apigenin drives the production of reactive oxygen species and initiates a mitochondrial mediated cell death pathway in prostate epithelial cells. Prostate 63:2 (2005), 131–142.
35. [35] Kelly, P.N., Puthalakath, H., Adams, J.M., Strasser, A., Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma. Blood 109:11 (2007), 4907–4913.
36. [36] Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., Abdulkadir, I.R., Lu, L., Irvin, D., Black, K.L., Yu, J.S., Analysis of gene expression and chemoresistance of CD133 + cancer stem cells in glioblastoma. Mol. Cancer, 5, 2006, 67.
37. [37] Wu, S., Wang, X., Chen, J., Chen, Y., Autophagy of cancer stem cells is involved with chemoresistance of colon cancer cells. Biochem. Biophys. Res. Commun. 434:4 (2013), 898–903.
38. [38] Shukla, S., Gupta, S., Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Mol. Cancer Ther. 5:4 (2006), 843–852.
39. [39] Roy, S., Singh, R.P., Agarwal, C., Siriwardana, S., Sclafani, R., Agarwal, R., Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype. Cell Cycle 7:12 (2008), 1828–1835.
40. [40] Uygur, B., Wu, W.S., SLUG promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis. Mol. Cancer, 10, 2011, 139.
41. [41] Nakada, M., Okada, Y., Yamashita, J., The role of matrix metalloproteinases in glioma invasion. Front. Biosci. 8 (2003), E261–E269.
42. [42] Zhu, Y., Wu, J., Li, S.Q., Wang, X., Liang, Z., Xu, X.L., Xu, X., Hu, Z.H., Lin, Y.W., Chen, H., et al. Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer. Mol. Med. Rep. 11:2 (2015), 1004–1008.
43. [43] Shukla, S., Gupta, S., Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappa B activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappa B-responsive genes. Clin. Cancer Res. 10:9 (2004), 3169–3178.
44. [44] Qin, Y., Zhao, D., Zhou, H.G., Wang, X.H., Zhong, W.L., Chen, S., Gu, W.G., Wang, W., Zhang, C.H., Liu, Y.R., et al. Apigenin inhibits NF-kappaB and snail signaling, EMT and metastasis in human hepatocellular carcinoma. Oncotarget, 2016.
45. [45] Noh, H.J., Sung, E.G., Kim, J.Y., Lee, T.J., Song, I.H., Suppression of phorbol-12-myristate-13-acetate-induced tumor cell invasion by apigenin via the inhibition of p38 mitogen-activated protein kinase-dependent matrix metalloproteinase-9 expression. Oncol. Rep. 24:1 (2010), 277–283.
46. [46] Wang, M.L., Chiou, S.H., Wu, C.W., Targeting cancer stem cells: emerging role of Nanog transcription factor. Onco Targets Ther. 6 (2013), 1207–1220.
47. [47] Liu, L., Peng, Z.J., Xu, Z.Z., Wei, X., Effect of luteolin and apigenin on the expression of Oct-4, Sox2, and c-Myc in dental pulp cells with in vitro culture. Biomed. Res. Int., 2015.
48. [48] Chen, T.T., Yuan, D.T., Wei, B., Jiang, J., Kang, J.H., Ling, K., Gu, Y.J., Li, J.S., Xiao, L., Pei, G., E-cadherin-mediated cell-cell contact is critical for induced pluripotent stem cell generation. Stem Cells 28:8 (2010), 1315–1325.
49. [49] Maier, T., Guell, M., Serrano, L., Correlation of mRNA and protein in complex biological samples. FEBS Lett. 583:24 (2009), 3966–3973.
50. [50] Greenbaum, D., Colangelo, C., Williams, K., Gerstein, M., Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol., 4(9), 2003.
51. [51] McCubrey, J.A., Abrams, S.L., Stadelman, K., Chappell, W.H., LaHair, M., Ferland, R.A., Steelman, L.S., Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. Adv. Enzym. Regul. 50 (2010), 285–307.
52. [52] Bitting, R.L., Armstrong, A.J., Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr. Relat. Cancer 20:3 (2013), R83–R99.
53. [53] Hossini, A.M., Quast, A.S., Plotz, M., Grauel, K., Exner, T., Kuchler, J., Stachelscheid, H., Eberle, J., Rabien, A., Makrantonaki, E., et al. PI3K/AKT signaling pathway is essential for survival of induced pluripotent stem cells. PLoS One, 11(5), 2016.
54. [54] Ciuffreda, L., Falcone, I., Incani, U.C., Del Curatolo, A., Conciatori, F., Matteoni, S., Vari, S., Vaccaro, V., Cognetti, F., Milella, M., PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. Adv. Biol. Regul. 56 (2014), 66–80.
55. [55] Georgescu, M.M., PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer 1:12 (2010), 1170–1177.
56. [56] Lonergan, P.E., Tindall, D.J., Androgen receptor signaling in prostate cancer development and progression. J. Carcinog., 10, 2011, 20.